Details for Patent: 8,039,451
✉ Email this page to a colleague
Which drugs does patent 8,039,451 protect, and when does it expire?
Patent 8,039,451 protects EUCRISA and is included in one NDA.
Protection for EUCRISA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has ninety-six patent family members in twenty-five countries.
Summary for Patent: 8,039,451
| Title: | Boron-containing small molecules |
| Abstract: | This invention relates to compounds useful for treating fungal infections, more specifically topical treatment of onychomycosis and/or cutaneous fungal infections. This invention is directed to compounds that are active against fungi and have properties that allow the compound, when placed in contact with a patient, to reach the particular part of the skin, nail, hair, claw or hoof infected by the fungus. In particular the present compounds have physiochemical properties that facilitate penetration of the nail plate. |
| Inventor(s): | Baker; Stephen J. (Mountain View, CA), Akama; Tsutomu (Sunnyvale, CA), Bellinger-Kawahara; Carolyn (Redwood City, CA), Hernandez; Vincent S. (Watsonville, CA), Hold; Karin M. (Belmont, CA), Leyden; James J. (Malvern, PA), Maples; Kirk (San Jose, CA), Plattner; Jacob J. (Berkeley, CA), Sanders; Virginia (San Francisco, CA), Zhang; Yong-Kang (San Jose, CA) |
| Assignee: | Anacor Pharmaceuticals, Inc. (Palo Alto, CA) |
| Application Number: | 12/507,010 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,039,451 |
|
Patent Claim Types: see list of patent claims | Compound; Composition; Formulation; |
Drugs Protected by US Patent 8,039,451
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anacor Pharms Inc | EUCRISA | crisaborole | OINTMENT;TOPICAL | 207695-001 | Dec 14, 2016 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,039,451
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2343304 | ⤷ Sign Up | CA 2020 00022 | Denmark | ⤷ Sign Up |
| European Patent Office | 2343304 | ⤷ Sign Up | 301049 | Netherlands | ⤷ Sign Up |
| European Patent Office | 2343304 | ⤷ Sign Up | LUC00157 | Luxembourg | ⤷ Sign Up |
| European Patent Office | 2343304 | ⤷ Sign Up | PA2020524 | Lithuania | ⤷ Sign Up |
| European Patent Office | 2343304 | ⤷ Sign Up | 122020000038 | Germany | ⤷ Sign Up |
| European Patent Office | 2343304 | ⤷ Sign Up | 2020C/531 | Belgium | ⤷ Sign Up |
| European Patent Office | 2343304 | ⤷ Sign Up | 132020000000082 | Italy | ⤷ Sign Up |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
